Immunotherapies have revolutionized the treatment paradigms of various types of cancers.
However, most of these immunomodulatory strategies focus on harnessing adaptive …

Immune checkpoint blockade, which blocks inhibitory signals of T cell activation, has shown
tremendous success in treating cancer, although success still remains limited to a fraction of …

Transforming growth factor-β (TGFβ) signalling controls multiple cell fate decisions during
development and tissue homeostasis; hence, dysregulation of this pathway can drive …

Transforming growth factor-β (TGF-β) signaling regulates cell-specific programs involved in
embryonic development, wound-healing, and immune homeostasis. Yet, during tumor …

Transforming growth factor (TGF)-β is a crucial enforcer of immune homeostasis and
tolerance, inhibiting the expansion and function of many components of the immune system …

It is well established that organs of future metastasis are not passive receivers of circulating
tumour cells, but are instead selectively and actively modified by the primary tumour before …

Elimination of cancer stem cells (CSCs) and reinvigoration of antitumor immunity remain
unmet challenges for cancer therapy. Tumor-associated macrophages (TAMs) constitute the …

Neutrophils are indispensable antagonists of microbial infection and facilitators of wound
healing. In the cancer setting, a newfound appreciation for neutrophils has come into view …

The TGF-β signaling pathway governs key cellular processes under physiologic conditions
and is deregulated in many pathologies, including cancer. TGF-β is a multifunctional …

The emergence of disseminated metastases remains the primary cause of mortality in
cancer patients. Formation of the pre-metastatic niche (PMN), which precedes the …